Catalent's GPEx technology creates stable, high-yielding mammalian cell lines

Catalent’s proprietary GPEx^® technology creates stable, high-yielding mammalian cell lines with high speed and efficiency, getting customer’s drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.